The Biotech That Tried to Dethrone Padcev and Lost

This is a classic catch-22 in oncology drug development. Running a massive head-to-head trial against Padcev would take years and hundreds of millions of dollars. For a company Bicycle's size, that's like asking a local restaurant to outspend McDonald's on advertising. The math just doesn't work.

So Bicycle made the painful but arguably rational call. The Duravelo-2 trial is being converted from a Phase 2/3 to a smaller randomized Phase 2. Patients already enrolled will finish treatment, but new enrollment is shutting down. The company is also discontinuing two related trials: Duravelo-3 (zelenectide in breast cancer) and Duravelo-4 (zelenectide in non-small cell lung cancer).

Padcev's Iron Grip

To understand why Bicycle retreated, you have to understand just how entrenched Padcev has become.

Padcev (enfortumab vedotin) first won FDA approval back in 2019. Pfizer acquired its developer, Seagen, in a $43 billion deal in 2023, and since then the drug has only gotten stronger. It secured approval as a first-line treatment in combination with Keytruda. Another label expansion came through in November 2025.

The antibody-drug conjugate (ADC) space in bladder cancer is crowded and getting more competitive. There are roughly 60 active clinical trials involving ADCs in urothelial cancer, but most are stuck in early phases. Few have cracked Phase 3. And with Padcev already the standard of care, the bar for new entrants keeps rising. It's not enough to work; you have to prove you work better than a drug that already works really well.

What Bicycle Is Betting On Now

With the bladder cancer dream shelved (at least internally), Bicycle is channeling its remaining resources into two areas.

First up: BT5528 (nuzefatide pevedotin), a drug conjugate targeting a protein called EphA2. This one is aimed at metastatic pancreatic cancer, a notoriously hard-to-treat disease with few good options. The company plans to share Phase 1/2 combination data with nivolumab (another immunotherapy) in the first half of 2026. If pancreatic cancer is the final boss of oncology, at least Bicycle won't face an entrenched competitor the way it did with Padcev.

Second: Bicycle Radioconjugates (BRCs), a newer twist on the company's core technology. Instead of delivering a chemical payload to tumors, these use radioactive isotopes. The first candidate (BT1702) is expected to enter the clinic in 2027. Radiopharmaceuticals are one of the hottest areas in oncology right now, so this pivot has strategic logic behind it.

The Numbers Game

The restructuring isn't just about pipeline choices; it's about cash. By cutting 30% of its staff and narrowing its focus, Bicycle expects to slash annual operating expenses by roughly 50%. The company had $628 million in cash at the end of 2025, and the leaner operation should stretch that runway into 2030.

That's actually the silver lining here. With nearly five years of cash on hand, Bicycle has time to prove out its remaining bets. Analysts seem cautiously aligned: Oppenheimer lowered its price target from $44 to $36 but kept an Outperform rating. Citizens dropped to $8 from $12 while also maintaining a positive outlook. Both pointed to the company trading at a negative enterprise value, meaning the cash pile alone is worth more than what the market is pricing the stock at.

A Cautionary Tale for the ADC Gold Rush

Bicycle's story is a useful reminder of how brutal the competitive dynamics in oncology can be. The science behind zelenectide wasn't bad. A 58% response rate is genuinely meaningful for bladder cancer patients. But in a world where the incumbent already hits 68%, "good" isn't good enough to justify the investment required to get across the regulatory finish line.

This wasn't Bicycle's first restructuring, either. The company cut 25% of its workforce back in August 2025. Two rounds of layoffs in seven months tells you how quickly the ground shifted.

For Bicycle, the path forward is narrower but clearer. Pancreatic cancer and radioconjugates represent less crowded arenas where the company's unique peptide-based platform might find a better competitive position. The question is whether investors, and the remaining 200 or so employees, have the patience to see it through.

Astellas Just Killed a Drug No One's Been Able to Make Work

Astellas pulled the plug on its STING inhibitor trial for Sjögren's syndrome before it could even generate human data. The decision says as much about a notoriously undruggable target as it does about where Big Pharma is placing its bets.